{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"MLRLLZWQYJJPEX-UHFFFAOYSA-N","prefName":"CUMYL-NBMINACA","symbol":"CUMYL-NBMINACA","iupacName":"1-(2-bicyclo[2.2.1]heptanylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide","aliases":["CUMYL-NBMINACA","SGT-152","Cumyl-BC[2.2.1]HpMINACA"],"cas":"1631074-60-6","pubchemCid":"117650372","chebiId":null,"smiles":"CC(C)(C1=CC=CC=C1)NC(=O)C2=NN(C3=CC=CC=C32)CC4CC5CCC4C5","molecularFormula":"C25H29N3O","molecularWeight":387.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/117650372"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic pathway: Cumyl-NBMINACA is a synthetic molecule, chemically classed among the indazole-3-carboxamides, with no known link to a plant or a living organism.","originNote":"Synthetic molecule: the sources consulted class it among synthetic cannabinoids, with no plant origin reported in those sources. Purified standards of Cumyl-NBMINACA were isolated from herbal blend material within the European ADEBAR plus project (Giorgetti et al., 2025). Pulver et al. (2023) report that the cyclobutylmethyl and norbornylmethyl side chains allowed these substances to circumvent German legislation, and that the market life cycle of these substances was less than one year.","discovered":""},"pharmacology":{"summaryFr":"Cumyl-NBMINACA is a synthetic cannabinoid of the indazole-3-carboxamide family, a full agonist at the CB1 cannabinoid receptor. Pulver et al. (2023) report, for the norbornylmethyl series, an affinity constant Ki between 0.25 and 1.87 nM, the indazole being the most affine derivative, with an EC50 from 1.78 to 169 nM for the same series. Giorgetti et al. (2025) described its phase I metabolism from two authentic urine samples, in which 13 phase I metabolites were identified, and proposed urinary biomarkers based on the norbornylmethyl chain. Its legal status in France remains to be settled: it is not named on the ANSM list, and whether it meets the generic definition of indazole-3-carboxamides depends on how the cycloalkylmethyl substituent is interpreted. No clinical study and no controlled human toxicology data are published in the sources consulted.","receptorSummaryFr":"Full agonist at the CB1 receptor. Pulver et al. (2023) report that the six cyclobutylmethyl and norbornylmethyl derivatives they studied are all full CB1 agonists, compared with Δ9-THC. For the norbornylmethyl series, the affinity constant Ki ranges from 0.25 to 1.87 nM, the indazole being the most affine derivative, and the EC50 from 1.78 to 169 nM, the indazole tending to be the most potent of the three. The abstracts consulted report neither a CB2 binding constant nor any action on TRPV1 or GPR55.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":95,"reported":"Ki de 0,25 à 1,87 nM pour la série norbornylméthyle, l'indazole étant le plus affin ; EC50 de 1,78 à 169 nM, l'indazole tendant à être le plus puissant (Pulver et coll., 2023)","confidence":"medium"}],"references":[{"label":"Giorgetti et coll., métabolisme de phase I humain de trois cannabinoïdes de synthèse à noyau cumyle dont le Cumyl-NBMINACA, Drug Test Anal, 2025","pmid":"39218806","doi":"10.1002/dta.3791","url":"https://pubmed.ncbi.nlm.nih.gov/39218806/"},{"label":"Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des cannabinoïdes de synthèse à chaînes cyclobutylméthyle et norbornylméthyle, Drug Test Anal, 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, définition des dérivés du 3-carboxamide indazole)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"OICS, Liste verte des substances psychotropes sous contrôle international, édition 2026","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-NBMINACA, CID 117650372","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/117650372"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":10},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":4},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":10},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":12},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":15}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"evolving","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"At European Union level, no harmonised control measure is documented in the sources consulted: control falls under national legislation.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Cumyl-NBMINACA is not named on the ANSM consolidated list of narcotics (updated 16 February 2026). The relevant framework is the generic definition of indazole-3-carboxamide derivatives, listed in annex IV of that consolidated list. The amide condition is met: the cumyl group is among the listed substituents. The condition on the N1 nitrogen requires a cycloalkylmethyl-type substituent, and the norbornylmethyl chain is a bicyclic ring: the text does not say whether this case falls within that category. As this cannot be decided with certainty, the French status is classed as evolving. The international status is separate: the compound is not listed on the INCB Green List 2026.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Giorgetti et coll., métabolisme de phase I humain de trois cannabinoïdes de synthèse à noyau cumyle dont le Cumyl-NBMINACA, Drug Test Anal, 2025","pmid":"39218806","doi":"10.1002/dta.3791","url":"https://pubmed.ncbi.nlm.nih.gov/39218806/"},{"label":"Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des cannabinoïdes de synthèse à chaînes cyclobutylméthyle et norbornylméthyle, Drug Test Anal, 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, définition des dérivés du 3-carboxamide indazole)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"OICS, Liste verte des substances psychotropes sous contrôle international, édition 2026","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-NBMINACA, CID 117650372","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/117650372"}],"meta":{"slug":"cumyl-nbminaca","url":"https://en.phytogrammes.com/wiki/cumyl-nbminaca","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}